ITI Pharma & Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • (-0.95%)Nav, as on 16-01-2026

  • Previous Nav

  • Net Change on 16-01-2026

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 1.60 22.20 15.21 0.92 8,264.71
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - Cumulative Option Jul 13, 2018 2.65 27.41 17.51 1.02 6,455.55
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 1.02 24.44 16.72 0.91 3,989.42
Mirae Asset Healthcare Fund Direct Growth Jul 02, 2018 3.09 22.93 16.35 0.48 2,770.84
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 0.76 23.14 15.96 0.62 1,310.50

Fund Holdings as on 31-December-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Apollo Hospitals Enterprise Limited

  • Max Healthcare Institute Limited

  • Torrent Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Fortis Healthcare Limited

  • Cohance Lifesciences Limited

  • Lupin Limited

  • Alkem Laboratories Limited

  • Aster DM Healthcare Limited

  • Neuland Laboratories Limited

  • Wockhardt Limited

  • TREPS 01-Jan-2026

  • Abbott India Limited

  • Laurus Labs Limited

  • Cipla Limited

  • Glenmark Pharmaceuticals Limited

  • Dr. Reddy's Laboratories Limited

  • Mankind Pharma Limited

  • Sai Life Sciences Limited

  • FDC Limited

  • IPCA Laboratories Limited

  • Healthcare Global Enterprises Limited

  • Sumitomo Chemical India Limited

  • SBI Life Insurance Company Limited

  • Biocon Limited

  • Orchid Pharma Limited

  • Onesource Specialty Pharma Limited

  • Piramal Pharma Limited

  • Rainbow Childrens Medicare Limited

  • Park Medi World Limited

  • Linde India Limited

  • Standard Glass Lining Technology Ltd

  • GlaxoSmithKline Pharmaceuticals Limited

  • Poly Medicure Limited

  • Caplin Point Laboratories Limited

  • Supriya Lifescience Limited

  • AstraZeneca Pharma India Limited

  • Shilpa Medicare Limited

  • Zydus Lifesciences Limited

  • Syngene International Limited

  • Net Receivables / (Payables)

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Pesticides & Agrochemicals

  • Insurance

  • Industrial Gases & Fuels

  • Engineering - Industrial Equipments

  • Medical Equipment/Supplies/Accessories

  • Business Support

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹223.80 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended down ₹-0.16(-0.95%)yesterday to ₹16.6807.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com